Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients.
López-Maraver M, Serrano-Combarro A, Atienza-Mateo B, Del Val N, Casafont-Solé I, Melero-Gonzalez RB, Pérez-Linaza A, Calvo Gutiérrez J, Mena-Vázquez N, Vegas-Revenga N, Domínguez-Casas L, Loarce Martos J, Peralta Ginés CA, Diez Morrondo C, Pérez Albaladejo L, López Sánchez R, Manzano Canabal MG, Brandy-García AM, López Viejo P, Bonilla G, Maiz-Alonso O, Carrasco-Cubero C, Garijo Bufort M, Moreno M, Urruticoechea-Arana A, Ordóñez-Palau S, González-Montagut C, Giner Serret E, De Dios Jiménez De Aberasturi JR, Lozano Morillo F, Vázquez Rodríguez T, Carreira PE, Blanco Madrigal JM, Miguel Ibáñez B, Rodríguez López M, Fernández-Díaz C, Loricera J, Ferraz-Amaro I, Ferrer-Pargada D, Castañeda S, Blanco R; Spanish Collaborative Group of Abatacept in Interstitial Lung Disease Associated with Rheumatoid Arthritis.
López-Maraver M, et al. Among authors: loricera j.
Semin Arthritis Rheum. 2024 Oct;68:152517. doi: 10.1016/j.semarthrit.2024.152517. Epub 2024 Jul 18.
Semin Arthritis Rheum. 2024.
PMID: 39067148